Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
Summary
Third Opinion Trial Synopsis:
Scientists are testing a new treatment for people with a type of cancer called multiple myeloma and kidney failure. The treatment uses a drug called daratumumab along with other drugs like bortezomib, dexamethasone, and thalidomide or lenalidomide. Daratumumab can help stop cancer cells from growing and spreading, while bortezomib helps kill the cancer cells. Dexamethasone is a type of medicine that is commonly used to treat multiple myeloma, and thalidomide and lenalidomide can stop tumors from growing. This new treatment could be a good way to help people who have just been diagnosed with multiple myeloma and kidney failure.
Scientists are testing a new treatment for people with a type of cancer called multiple myeloma and kidney failure. The treatment uses a drug called daratumumab along with other drugs like bortezomib, dexamethasone, and thalidomide or lenalidomide. Daratumumab can help stop cancer cells from growing and spreading, while bortezomib helps kill the cancer cells. Dexamethasone is a type of medicine that is commonly used to treat multiple myeloma, and thalidomide and lenalidomide can stop tumors from growing. This new treatment could be a good way to help people who have just been diagnosed with multiple myeloma and kidney failure.
*Third Opinion AI Generated Synopsis
Trial Summary
This phase II trial studies how well daratumumab-based therapy works in treating patients with newly diagnosed multiple myeloma with kidney failure. Daratumumab-based therapy includes daratumumab, bortezomib, dexamethasone, and thalidomide or lenalidomide. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Bortezomib is a drug that prevents myeloma cells from getting rid of their waste products, leading to being targeted for death. Dexamethasone is a steroid that is commonly used, either alone or in combination with other drugs, to treat multiple myeloma. Lenalidomide and thalidomide may stop the growth of multiple myeloma by blocking the growth of new blood vessels necessary for tumor growth. Giving daratumumab, bortezomib, dexamethasone, and thalidomide or lenalidomide may be a good way to treat patients with newly diagnosed multiple myeloma with kidney failure.
This phase II trial studies how well daratumumab-based therapy works in treating patients with newly diagnosed multiple myeloma with kidney failure. Daratumumab-based therapy includes daratumumab, bortezomib, dexamethasone, and thalidomide or lenalidomide. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Bortezomib is a drug that prevents myeloma cells from getting rid of their waste products, leading to being targeted for death. Dexamethasone is a steroid that is commonly used, either alone or in combination with other drugs, to treat multiple myeloma. Lenalidomide and thalidomide may stop the growth of multiple myeloma by blocking the growth of new blood vessels necessary for tumor growth. Giving daratumumab, bortezomib, dexamethasone, and thalidomide or lenalidomide may be a good way to treat patients with newly diagnosed multiple myeloma with kidney failure.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: